Latest pharmacokinetics Stories
SAN FRANCISCO, May 16, 2013 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 2013 UBS Global Healthcare Conference in New York at the Sheraton New York Hotel on Tuesday, May 21, 2013 at 10:00 a.m. Eastern time. The presentation will be accessible via a Webcast through a link posted in the Investor Relations, Events Calendar section of the Nektar website: http://www.nektar.com. This...
EXTON, Pa., April 30, 2013 /PRNewswire/ -- Absorption Systems, a global leader in preclinical contract testing of drugs, biologics, and medical devices, is pleased to announce that Vatsala Naageshwaran, Associate Director of Scientific Operations, will present a talk at the Disso 2013 Conference on May 3(rd) in Mumbai, India. The title of her presentation is "Permeability classification of highly variable drugs using the in vitro Caco-2 assay." The symposium, convened under the...
Discovery widens treatment options for neurodegenerative and central nervous system disease Neurodegenerative and central nervous system (CNS) diseases represent a major public health issue affecting at least 20 million children and adults in the United States alone. Multiple drugs exist to treat and potentially cure these debilitating diseases, but 98 percent of all potential pharmaceutical agents are prevented from reaching the CNS directly due to the blood-brain barrier. Using...
-Oxycodone DETERx® resistant to tampering via chewing and crushing CANTON, Mass., April 17, 2013 /PRNewswire/ -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced top-line results from its recently completed Phase I clinical trial for Oxycodone DETERx®, its extended-release, abuse-deterrent, multi-particulate product in a capsule form. The product utilizes Collegium's DETERx®...
MIAMI, April 16, 2013 /PRNewswire-USNewswire/ -- In a study published in today's issue of Nature Communications, researchers from Florida International University's Herbert Wertheim College of Medicine describe a revolutionary technique they have developed that can deliver and fully release the anti-HIV drug AZTTP into the brain. Madhavan Nair, professor and chair, and Sakhrat Khizroev, professor and vice chair of the HWCOM's Department of Immunology, used magneto-electric...
Self-identifies as a Biopharmaceutics Classification System (BCS), Bioequivalence, and Bioavailability Testing Facility EXTON, Pa., March 25, 2013 /PRNewswire/ -- The preclinical contract research organization Absorption Systems, a global leader in pharmacokinetic testing of drugs and the world leader in the in-vitro classification of drugs according to the Biopharmaceutics Classification System (BCS), announces that it has registered with the United States Food and Drug...
Eckert & Ziegler Vitalea Science (EZVS) and BioCore Co. Ltd., leading bioanalytical contract research organizations (CRO), are pleased to announce the initiation of an agreement to co-market complementary services in support of clinical drug development for the pharmaceutical industry. Davis, California and Seoul, South Korea (PRWEB) January 17, 2013 Eckert & Ziegler Vitalea Science (EZVS) and BioCore Co. Ltd., leading bioanalytical contract research organizations (CRO), are...
SAN FRANCISCO, Jan. 4, 2013 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 31st Annual J.P. Morgan Healthcare Conference in San Francisco at the Westin St. Francis Hotel on Wednesday, January 9, 2013 at 8:30 a.m. Pacific time. The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website:...
ANAHEIM, Calif., Jan. 2, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that it has signed a definitive agreement to acquire all issued and outstanding shares of BioVectra Inc., for an upfront payment of C$50 million. BioVectra is a supplier of contract manufacturing services to the global pharmaceutical and biotechnology industry and manufactures active pharmaceutical ingredients (API's), chemical intermediates, and bioprocessing reagents....
Lee Rannals for redOrbit.com – Your Universe Online Researchers have created a gel that can be painted onto the walls of blood vessels, which could eventually help save lives. The gel can help to prevent the inflammation that typically occurs when a stent is inserted to widen a narrowed artery or vein. This inflammation often counteracts the opening of the vessel that the stent was intended to achieve. The team wrote about the gel in the current issue of the online journal...
